The Inhibitory Effects of Vanillin on the Growth of Melanoma by Reducing Nuclear Factor-κB Activation.
B16F10
melanoma
nuclear factor-κB
vanillin
Journal
Advanced biomedical research
ISSN: 2277-9175
Titre abrégé: Adv Biomed Res
Pays: India
ID NLM: 101586897
Informations de publication
Date de publication:
2022
2022
Historique:
received:
06
09
2021
revised:
29
09
2021
accepted:
12
10
2021
entrez:
3
11
2022
pubmed:
4
11
2022
medline:
4
11
2022
Statut:
epublish
Résumé
Melanoma is skin cancer, and the treatments are not efficient enough. Therefore, finding new drugs seems to be an essential need. Vanillin, which is extracted from vanilla seed, has anti-cancer effects by reducing nuclear factor-κB (NF). We explored the anti-tumor effects of vanillin in the melanoma model and its possible mechanism. In the MTT assay, mice melanoma cells (B16F10) were treated with vanillin (1, 2, 3, 4, 5 μg/mL) for 24 and 48 h. In an animal model, B16F10 was subcutaneously injected into C57BL/6 mice. After the development of tumors, the mice were treated with 50 and 100 mg/kg/day of vanillin for 10 days. The tumor size and expression level of NF-κB protein were measured. In the MTT assay, vanillin in all concentrations significantly decreased B16F10 cell viability after 24 h incubation. The size of melanoma tumors was reduced in both doses 50 and 100 mg/kg/day in mice. NF-κB protein expression was decreased in the 100 mg/kg/day group in comparison with the control group. We found that vanillin by reducing NF-κB expression may have anti-tumor effects and reduced melanoma tumor size and cell viability.
Sections du résumé
Background
UNASSIGNED
Melanoma is skin cancer, and the treatments are not efficient enough. Therefore, finding new drugs seems to be an essential need. Vanillin, which is extracted from vanilla seed, has anti-cancer effects by reducing nuclear factor-κB (NF). We explored the anti-tumor effects of vanillin in the melanoma model and its possible mechanism.
Materials and Methods
UNASSIGNED
In the MTT assay, mice melanoma cells (B16F10) were treated with vanillin (1, 2, 3, 4, 5 μg/mL) for 24 and 48 h. In an animal model, B16F10 was subcutaneously injected into C57BL/6 mice. After the development of tumors, the mice were treated with 50 and 100 mg/kg/day of vanillin for 10 days. The tumor size and expression level of NF-κB protein were measured.
Results
UNASSIGNED
In the MTT assay, vanillin in all concentrations significantly decreased B16F10 cell viability after 24 h incubation. The size of melanoma tumors was reduced in both doses 50 and 100 mg/kg/day in mice. NF-κB protein expression was decreased in the 100 mg/kg/day group in comparison with the control group.
Conclusion
UNASSIGNED
We found that vanillin by reducing NF-κB expression may have anti-tumor effects and reduced melanoma tumor size and cell viability.
Identifiants
pubmed: 36325172
doi: 10.4103/abr.abr_280_21
pii: ABR-11-68
pmc: PMC9621346
doi:
Types de publication
Journal Article
Langues
eng
Pagination
68Informations de copyright
Copyright: © 2022 Advanced Biomedical Research.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Toxicol Appl Pharmacol. 2019 Feb 15;365:9-18
pubmed: 30610879
BMC Med Imaging. 2008 Oct 16;8:16
pubmed: 18925932
Clin Cancer Res. 2000 Jun;6(6):2573-81
pubmed: 10873114
Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):183-93
pubmed: 11316563
Food Chem Toxicol. 2011 Jan;49(1):25-30
pubmed: 20807560
Comput Math Methods Med. 2020 Nov 16;2020:8836493
pubmed: 33273963
J Invest Dermatol. 2018 Oct;138(10):2205-2215
pubmed: 29580868
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
Int J Med Sci. 2020 Feb 4;17(3):403-413
pubmed: 32132875
Int J Mol Sci. 2017 Mar 01;18(3):
pubmed: 28257048
Life Sci. 2017 Apr 1;174:50-58
pubmed: 28238718
Mol Pharmacol. 2009 Jan;75(1):151-7
pubmed: 18835982
J Agric Food Chem. 2018 Jun 6;66(22):5563-5573
pubmed: 29790745
Int J Oncol. 2017 Apr;50(4):1341-1351
pubmed: 28259926
Pigment Cell Res. 2006 Apr;19(2):112-24
pubmed: 16524427
In Vivo. 2014 Nov-Dec;28(6):1005-11
pubmed: 25398793
Anticancer Res. 2016 Nov;36(11):5743-5750
pubmed: 27793895
Mol Cell Biochem. 2018 Jan;438(1-2):35-45
pubmed: 28744811
Bioorg Med Chem. 2019 Jul 1;27(13):2893-2904
pubmed: 31104785
Biochim Biophys Acta. 2010 Oct-Dec;1799(10-12):775-87
pubmed: 20493977
J Sci Food Agric. 2013 Feb;93(3):429-38
pubmed: 23208984
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Int J Mol Sci. 2017 Feb 12;18(2):
pubmed: 28208679
Cancer Epidemiol. 2009 Aug;33(2):155-60
pubmed: 19679064
Adv Pharm Bull. 2020 Jul;10(3):458-463
pubmed: 32665906
Curr Allergy Asthma Rep. 2013 Feb;13(1):44-9
pubmed: 22956391
Eur J Pharm Sci. 2005 May;25(1):57-65
pubmed: 15854801
Int J Mol Sci. 2020 Apr 27;21(9):
pubmed: 32349210
Oncogene. 2006 Oct 30;25(51):6817-30
pubmed: 17072330
In Vivo. 2010 Jul-Aug;24(4):501-6
pubmed: 20668316
Oxid Med Cell Longev. 2016;2016:9734816
pubmed: 28077989
Pathol Res Pract. 2016 Sep;212(9):767-77
pubmed: 27493101